It is used for patients having metastasis as a combination with chemotherapy or as monotherapy, lapatinib is used first in combination with letrozole or HER2, ER (+) breast cancer patients as well for HER2 (+) in combination with capecitabine (41). This evidence concerns the gene ERBB2 and breast carcinoma.